BACKGROUND: Familial hyperaldosteronism type III (FH-III) is a rare autosomal dominant disease for which five missense mutations in KCNJ5 have been identified. FH-III has a wide phenotypic variability from spironolactone-responsive hyperaldosteronism to massive adrenal hypertrophy with drug-resistant hypertension. This variation has mainly been attributed to genotype, because, in contrast to other genotypes (G151R, T158A, I157S, and Y152C), (1) FH-III patients with G151E have shown milder phenotype, and (2) G151E-harboring cells were found to have rapid lethality due to much larger sodium conductance of the encoded channel (Kir3.4), which prevents adrenal hypertrophy. METHODS: Here we describe the clinical course of a sporadic case of FH-III, with de novo G151R mutation. RESULTS: The patient developed polyuria at around 1.5 years of age and developed hypertension and hypokalemia by 4 years of age. Thereafter, spironolactone treatment successfully ameliorated hyperaldosteronism for 7 years with no discernible adrenal enlargement. CONCLUSION: Diverse clinical severity in FH-III cannot be defined solely by KCNJ5 genotype.
BACKGROUND:Familial hyperaldosteronism type III (FH-III) is a rare autosomal dominant disease for which five missense mutations in KCNJ5 have been identified. FH-III has a wide phenotypic variability from spironolactone-responsive hyperaldosteronism to massive adrenal hypertrophy with drug-resistant hypertension. This variation has mainly been attributed to genotype, because, in contrast to other genotypes (G151R, T158A, I157S, and Y152C), (1) FH-III patients with G151E have shown milder phenotype, and (2) G151E-harboring cells were found to have rapid lethality due to much larger sodium conductance of the encoded channel (Kir3.4), which prevents adrenal hypertrophy. METHODS: Here we describe the clinical course of a sporadic case of FH-III, with de novo G151R mutation. RESULTS: The patient developed polyuria at around 1.5 years of age and developed hypertension and hypokalemia by 4 years of age. Thereafter, spironolactone treatment successfully ameliorated hyperaldosteronism for 7 years with no discernible adrenal enlargement. CONCLUSION: Diverse clinical severity in FH-III cannot be defined solely by KCNJ5 genotype.
Authors: Natividad Pons Fernández; Francisca Moreno; Julia Morata; Ana Moriano; Sara León; Carmen De Mingo; Ángel Zuñiga; Fernando Calvo Journal: Rev Endocr Metab Disord Date: 2019-03 Impact factor: 6.514
Authors: S Monticone; M Tetti; J Burrello; F Buffolo; R De Giovanni; F Veglio; T A Williams; P Mulatero Journal: J Hum Hypertens Date: 2017-04-27 Impact factor: 3.012
Authors: Teresa M Seccia; Brasilina Caroccia; Elise P Gomez-Sanchez; Celso E Gomez-Sanchez; Gian Paolo Rossi Journal: Endocr Rev Date: 2018-12-01 Impact factor: 19.871
Authors: Georgios Daniil; Fabio L Fernandes-Rosa; Jean Chemin; Iulia Blesneac; Jacques Beltrand; Michel Polak; Xavier Jeunemaitre; Sheerazed Boulkroun; Laurence Amar; Tim M Strom; Philippe Lory; Maria-Christina Zennaro Journal: EBioMedicine Date: 2016-10-04 Impact factor: 8.143